iabetes can be considered as a cardiovascular disease leading to the premature death of patients. The increase in cardiovascular risk has been extensively investigated and is associated with a cluster of adverse factors. The effects of various treatments used to affect the pathogenesis of the atherosclerotic process have been investigated in many large trials. A number of issues make the interpretation and comparison of these trials complicated, and in particular the use of a single primary end point such as mortality has been replaced with composite end points. The effects of risk factors and interventions on coronary heart disease (CHD) risk has been converted to cardiovascular disease (CVD) risk for understandable reasons, but this makes the interpretation and comparison of results even more complex. This review provides a critical analysis of outcome studies, highlighting differences in design, end points, patient inclusion and definitions in recent cardiovascular diabetology trials, and examines the potential pitfalls in making unjustified comparisons.Br J Diabetes Vasc Dis 2006; 6:111—18
American Diabetes Association.Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care1998 ;21:1551-9.
2.
Donnelly R.Managing cardiovascular risk in patients with diabetes. Br J Diabetes Vasc Dis2005;5:325-9.
3.
McCallum RW, Fisher M.From 4S to FIELD and PROactive: 10 years of CV trials in people with diabetes . Br J Diabetes Vasc Dis2005;5:218-25.
4.
Anonymous.JBS 2: Joint British Societies' guidelines on the prevention of cardiovascular disease in clinical practice. Heart2005;91(suppl 5):v1-v52.
5.
Ross R.The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature1993;362:801-09.
6.
Lampe FC, Walker M., Shaper AG, Brindle PM, Whincup PH, Ebrahim S.Endpoints for predicting coronary risk must be clarified. BMJ2001; 323:396-7.
7.
Scandinavian Simvastatin SurvivalStudy Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344: 1383-9.
8.
Sacks F., Pfeffer M., Moye L. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med1996;335:1001-09.
9.
Goldberg RB, Mellies MJ, Sacks FM et al. Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial. Circulation1998;98:2513-19.
10.
The Long Term Intervention with Pravastatin in Ischaemic Heart Disease (LIPID) Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med1998;339:1349-57.
11.
Keech A., Colquohoun D., Best J. et al. Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose. Results from the LIPID trial. Diabetes Care2003;26:2713-21.
12.
The Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med1999;341:410-18.
13.
Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364:685-96.
14.
Dormandy JA , Charbonnel B., Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (Prospective pioglitazone Clinical Trial in Macrovascular events): a randomized controlled trial. Lancet2005;366:1279-89.
15.
The FIELD 5. The FIELD study Investigators.Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet2005;366:1849-61.
16.
The IONA study group.Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomized trial. Lancet2002;359:1269-75.
17.
Scott JF, Robinson GM, French JM et al. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycaemia. Stroke1999;30:793-9.
18.
UK Prospective Diabetes Study Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.
19.
UK Prospective Diabetes Study Group.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998;352:854-65.
20.
UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ1998;317:703-13.
21.
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002;359:1004-10.
22.
PROGRESS Collaborative Group.Randomised trial of a perindopril-based blood pressure regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet2001;358:1033-41.
23.
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet2000;355:253-9.
24.
Anonymous.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360:7-22.
25.
Gent M.A randomised blinded trial of clopidogrel versus aspirin in patients at high risk of ischaemic events (CAPRIE)Lancet1996 ;348: 1329-39.
26.
Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W., Topol EJAmplified benefits of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol2002;90:625-7.
27.
Yki-Jarvinen H.The PROactive study: some answers, many questions . Lancet2005;366:1241-2.
28.
Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med1993;329: 1456-62.
29.
Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med2001;345:861-9.
30.
Parving H-H. , Lehnert H., Brochner-Mortensen J.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes . N Engl J Med2001;345:870-8.
31.
Dahlof B., Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet2005;366:895-906.
32.
Anonymous.Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288:2981-97.
33.
Malmberg K. , Ryden L., Wedel H. et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): Effects on mortality and morbidity. Eur Heart J2005;26: 650-61.
34.
Nathan DMSome answers, more controversy from UKPDS: United Kingdom Prospective Diabetes Study. Lancet1998;352:832-3.
35.
Blumfield JD , Sealey JE, Mann SJ et al. Beta-adrenergic blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens1999;12:451-9.
36.
Svensson P. , de Faire U., Sleight P., Yusuf S., Ostergen J.Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE Substudy . Hypertension2001;38:e28-e32.
37.
Marchioli R. , Barzi F., Bomba E. et al. GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) Prevenzione . Circulation2002;105:1897-903.
38.
Skyler JSPROactive: A Sad Tale of Inappropriate Analysis and Unjustified Interpretation . Clin Diab2006;24:63-5.
39.
Turner RC, Holman RR, Matthews DR et al. UKPDS VIII. Study design, progress and performance. Diabetologia1991;34:877-90.
